Camlin Fine Sciences reported a net loss of ₹30 crore in Q2 FY27, double the year-ago loss, despite revenue growth. Liquidity issues and soaring raw material costs crushed margins, prompting a ₹250 crore rights issue to stabilize the balance sheet.
For Camlin Fine Sciences, the September quarter was a story of revenue growth that never reached the bottom line. The specialty chemicals maker saw sales climb, but a severe liquidity crunch and runaway input costs turned that progress into a deeper loss.
The numbers show the tension. Revenue for Q2 FY27 was ₹491 crore, up 6.8% from a year ago. Yet the net loss widened to ₹30 crore from ₹14.95 crore in Q2 FY26. The net profit margin eroded by 280 basis points year-on-year to -6.1%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
Metric
CurrentQ2 FY27
PreviousQ1 FY27
Same quarter LYQ2 FY26
Revenue (₹ Cr)
491.0YoY +6.8%
519.9
459.8
Profit (₹ Cr)
-30.0YoY -101%
-33.6
-14.9
Net Profit Margin (%)
-6.1YoY -85%
-6.5
-3.3
The Liquidity Vise
Management, in an earnings call covered by Investing.com, pinpointed liquidity as the main culprit. To manage a stretched working capital cycle, the company used expensive channel financing on both purchases and sales. This added an estimated ₹190-200 crore to quarterly costs, directly hitting gross margins.
The strain showed elsewhere. Interest expense surged 49.9% sequentially to ₹21 crore. Cash reserves plummeted to ₹49.5 crore at the end of September from ₹108.6 crore at the end of FY26, as reported by scanx.trade.
A Segmental Split
Performance diverged sharply across businesses. The Specialty Ingredients segment, including blends and straights, was a relative bright spot. According to the company's investor presentation, its revenue grew 26% year-on-year.
In stark contrast, the Aroma segment collapsed. Revenue fell 41% and posted a negative 23.1% EBITDA margin, hurt by a product changeover and very low plant utilization. The Performance Chemicals segment also remained a drag with the Diphenol plant shut.
The Rights Issue Lifeline
Facing this cash burn, the board approved a ₹250 crore rights issue. Management told analysts the funds would first stabilize working capital, with about ₹130 crore earmarked to clear overdue payables. The balance is intended to fund growth that liquidity had prevented.
The promised payoff is a sharp recovery in the final quarter. Management guided for Q4 FY27 revenue above ₹600 crore and an EBITDA margin exceeding 10%, driven by the liquidity infusion and a targeted ramp-up in vanillin sales.
Key Points
A severe liquidity crunch, requiring costly channel financing, was the primary driver of margin erosion and a wider net loss.
Performance was bifurcated: the core Specialty Ingredients business grew, while the Aroma segment collapsed with negative margins.
A ₹250 crore rights issue is central to the recovery plan, aimed at normalizing working capital and funding pent-up growth.
Management expects a material turnaround only in Q4 FY27, projecting revenue above ₹600 crore and double-digit EBITDA margin.
“
Hexa Perspective
The quarter confirms that Camlin Fine Sciences' operational issues are fundamentally financial. The business can grow sales, but without a normalized balance sheet, every rupee of revenue comes at a punishing cost. The rights issue is a necessary repair, but its success hinges on execution and timing.
Investors are being asked to fund a fix for problems that have suppressed earnings for multiple quarters. The guidance for a Q4 rebound is ambitious, requiring both the capital raise to proceed smoothly and for raw material pressures to not worsen further. The stock's reaction—a slight uptick on results day—suggests the market is weighing this potential recovery against significant execution risk.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Camlin Fine Sciences' Q2 FY27 results?
Camlin Fine Sciences reported a net loss of ₹30 crore on revenue of ₹491 crore for the quarter ended September 2026. While revenue grew 6.8% year-on-year, the loss widened from ₹14.95 crore in Q2 FY26 due to severe margin pressure from liquidity constraints and high raw material costs.
Why did Camlin Fine Sciences report a net loss in Q2 FY27 despite revenue growth?
Camlin Fine Sciences' Q2 FY27 loss widened due to a severe liquidity crunch. The company used expensive channel financing to manage working capital, which added roughly ₹190-200 crore to quarterly costs. Soaring raw material prices, which management said have doubled since February, also could not be fully passed on to customers.
What caused the significant year-on-year decline in net profit margin for Camlin Fine Sciences in Q2 FY27?
Camlin Fine Sciences' net profit margin fell 280 basis points to -6.1% in Q2 FY27. The decline was driven by a gross margin squeeze, attributed by management to high raw material prices and, chiefly, liquidity issues that forced the use of costly channel financing, embedding interest costs into the cost of sales.
What drove the 49.9% quarter-on-quarter increase in interest expense for Camlin Fine Sciences in Q2 FY27?
Camlin Fine Sciences' interest expense rose 49.9% sequentially to ₹21 crore in Q2 FY27 due to the high cost of channel financing. Management explained on the earnings call that using this financing to bridge a liquidity gap added significant interest costs, which were reflected in both purchase and sales prices.
How did the performance of Camlin Fine Sciences' different segments contribute to Q2 FY27 results?
Camlin Fine Sciences' segment performance was split. The Specialty Ingredients segment grew, with straights revenue up 26% YoY. However, the Aroma segment revenue plunged 41% with a -23.1% EBITDA margin, and Performance Chemicals also posted a loss. This divergence left the consolidated business deep in the red.
What is the status of Camlin Fine Sciences' debt and working capital as of Q2 FY27?
As of September 2026, Camlin Fine Sciences' cash balance fell sharply to ₹49.5 crore from ₹108.6 crore at FY26-end, per scanx.trade. Total borrowings stood at ₹629.4 crore. The company faces a severe working capital squeeze, prompting a ₹250 crore rights issue to clear overdue payables and stabilize operations.
What guidance did Camlin Fine Sciences management provide for profitability and revenue in FY27?
During the Q2 earnings call, Camlin Fine Sciences management said the earlier FY27 target of ₹2,000 crore revenue and 10% EBITDA margin will not be achieved. They now expect a turnaround in Q4 FY27, projecting revenue above ₹600 crore and an EBITDA margin exceeding 10% following the rights issue.
Did Camlin Fine Sciences' Q2 FY27 results beat or miss analyst estimates?
Camlin Fine Sciences' Q2 FY27 results missed management's own earlier ambitions. Executives stated on the call that the company will not meet its previously guided FY27 targets. The quarter was characterized by operational strain rather than a clean earnings surprise versus external expectations.
How has Camlin Fine Sciences' stock price reacted to the Q2 FY27 results?
Following the Q2 FY27 results announcement, Camlin Fine Sciences' stock price was up about 3.3%, as reported by Investing.com. The muted positive reaction suggests some investors focused on the proposed ₹250 crore rights issue and recovery plan, despite the weak near-term numbers.
What are the specific supply chain risks currently facing Camlin Fine Sciences?
Camlin Fine Sciences faces supply chain risks from geopolitical tensions, which have doubled freight costs, and from volatile raw material prices. Management also cited competitive pressure from low-priced Chinese vanillin supply entering markets through alternate routes, though they expect anti-dumping enforcement to tighten.
Camlin Fine Sciences Q2 profit drop
Camlin Fine Sciences' net loss widened to ₹30 crore in Q2 FY27, a drop from a loss of ₹14.95 crore in the same quarter last year. The increased loss was driven by a severe liquidity crunch that raised financing costs and an inability to pass on doubled raw material prices to customers.
Camlin Fine Sciences Q2 FY27 results November 2026
Camlin Fine Sciences announced its Q2 FY27 results on November 14, 2026, for the quarter ended September 2026. The company reported a net loss of ₹30 crore on revenue of ₹491 crore and announced a board-approved ₹250 crore rights issue to address liquidity challenges.
Why did Camlin Fine Sciences profits plunge despite sales growth?
Camlin Fine Sciences' profits plunged despite sales growth because a severe liquidity crisis forced the use of expensive channel financing, adding significant cost. Simultaneously, raw material prices doubled, and the company could not fully pass these increases to customers, crushing gross margins.
